Daily Recap - WEDNESDAY
Join panelists Drs. Janet Pope, Richard Conway, Meral El Ramahi and Jack Cush recap the best presentations presented on day four of the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →What's hot
View all perspectives
What's Hot
EXXELERATE Study: Do High RF Titers Impact Response to TNF Inhibitors?
Dr. Jonathan Kay discusses abstract 2148 with Dr. Josef Smolen at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Bimekizumab in Active AS: 5 Year Study
Dr. Atul Deodhar reporting on abstract 0519 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cannabinoid Receptor in RA Patients
Dr. Arthur Kavanaugh discusses abstract 0025 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Treatments in SpA
Dr. Rachel Tate and Dr. Catherine Blakewell discuss treatment options patients in spondyloarthritis at the 2023 ACR Convergence meeting in San Diego, CA. Abstracts discussed include 0520, 0530, 0521 and 0529.
Watch video →
PR3+ in Lupus Nephritis
Dr. Jack Cush discusses abstract 2427 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Simulated Trials to Counter ORAL Survelliance
Dr. Jack Cush and Dr. Janet Pope at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Difficult to Treat axSpA
Dr. Peter Nash reports on abstracts 0514 and 0538 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Window of Opportunity in PsA
Dr. Peter Nash discusses a study that looks at the window of opportunity for treatment of PsA at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
TMP SMX Prophylaxis in GPA
Dr. Jack Cush and Dr. Janet Pope discuss abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The FOREMOST Study: Apremilast in PsA
Dr. Peter Nash reports on abstract 1691 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The SMART Study: Split Dose Oral Methotrexate
Dr. Jack Cush discusses abstract 1583 presented at the 2023 ACR Convergence meeting in San Diego.
Watch video →
Real World Experience with PEXIVAS Low Steroid Taper
Dr. Mike Putman discusses abstract 0725 with Dr. Sophie Nagle at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
Read more →
#ACRbest Abstracts – Day 2
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more.
Read more →
Effects of Apremilast on Cardiometabolic Effects in PsA
Dr. Peter Nash discusses abstract 1414 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
An Interview with Kevin Winthrop: Three Questions About COVID 19
Drs. Jack Cush and Kevin Winthrop discuss COVID 19 at 2023 ACR Convergence in San Diego, CA.
Watch video →
Biologics as First-line Therapy for PMR and GCA?
Dr. Eric Dein talks with Dr. Philip Seo, one of two panelists for the Great Debate: Should PMR and GCA Be Treated with Advanced Therapies at Disease Onset? at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
JAK inhibitors obviously have dominated a lot of the discussion in our therapeutic landscape over the last couple of years. What about their use in polymyalgia rheumatica? Let's consider.
Dr. John Cush RheumNow
2 years ago
CMAJ analysis of 28 studies & 24 million pts Rx opioids suggest a higher risk of opioid overdose w/: high-dose opioids, fentanyl, multiple opioid Rxs, overdose Hx, Dx of substance use, depression, bipolar, mental illness, pancreatitis https://t.co/FprgoaTvXR https://t.co/G0QjNJTezu
A TNR Panel discussion on controversies in PMR: diagnosis, imaging, PCP roles, Lumping vs. Splitting.
Featuring Drs. Sarah Mackie, Wolfgang Schmidt, and Len Calabrese.
Moderated by Dr. David Liew.
Recorded on 10/24/2023
Dr. John Cush RheumNow
2 years ago
#PMR Polymyalgia rheumatica is very common, yet there is little research on the Dx & Management of PMR by #PCPs! Mayo study prevalence 701 per 100,000 (women=870 and men =508 per 100,000 population). https://t.co/7JZFeRPRnn https://t.co/0JoaXL4qv0
Dr. John Cush RheumNow
2 years ago
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023.
https://t.co/Wdk4tvnlRz https://t.co/YFdvfbyrpJ
Narratives around polymyalgia rheumatica (PMR) often centre around “older people” or even “elderly”. And, indeed, the peak of the age distribution is in the mid-70s – not that everyone that age considers themselves old. Treating “young PMR” can be a very different proposition to treating someone in their seventies or eighties. It’s worth taking time to think this through.
Dr. John Cush RheumNow
2 years ago
Unpopular opinion: spinach can be bad for you
The title might have misled you; simply, Dr Stephen Paget’s analogy comparing the drastic response to steroids in #PMR to Popeye’s spinach stuck with me!
https://t.co/VNlY6O5YeE https://t.co/RZmbVL2EiZ
Dr. John Cush RheumNow
2 years ago
Methotrexate in OA
Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.
https://t.co/RHiRBxajc6 https://t.co/PCygEXKT8f
Dr. John Cush RheumNow
2 years ago
Subcutaneous Remsima, an infliximab biosimilar, has been FDA. Celltrion has rebranded this as Zymfentra, for maintenance therapy in adults with moderately to severely active Ulcerative colitis and Crohn's disease following (after giving IV infliximab) https://t.co/gvcssRuB92 https://t.co/dPYVi10KIA
The ACR has published its updated recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily.
Despite increasing treatment options to prevent and treat GIOP, many GC-treated patients are not evaluated or treated.
Dr. John Cush RheumNow
2 years ago
Korean Insurance matched (1:10) claims cohort study (2010-2017) found bronchiectasis in 5.3% of 4845 systemic sclerosis pts vs 1.9% of non-SSc controls (24,225). SSc pts have a signif higher risk of bronchiectasis (adj HR 2.63), thus a minor feature of SSc https://t.co/7oOBkpw2DM https://t.co/683I0mMmQI
Poster Hall